Affiliations 

  • 1 Global Compliance and Quality Director, Kantar Health, Cambridge, Wales, UK
  • 2 Professor and Executive Director, Center on Drugs & Public Policy, University of Maryland School of Pharmacy, Bethesda, MD, USA. Electronic address: [email protected]
  • 3 Director, Scientific & Health Policy Initiatives, ISPOR, Lawrenceville, NJ, USA
  • 4 Chief Science Officer, ISPOR, Lawrenceville, NJ, USA
  • 5 Health Policy Consultant, Save Your Skin Foundation, Toronto, ON, Canada
  • 6 Co-Editor-in-Chief, Value in Health and Professor, Health Economics, Centre for Health Economics, University of York, Heslington, York, England, UK
  • 7 Associate Professor, Director of Undergraduate Medical Ethics Curriculum, Centre for Biomedical Ethics, National University of Singapore, Singapore
  • 8 Chief Data Strategist, IBM Watson Health, Cambridge, MA, USA
  • 9 Vice President, Global Head Scientific Affairs, QuintilesIMS, Reading, England, UK
  • 10 Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland
  • 11 Associate Professor, University Sains Malaysia, Member of National Good Governance of Medicine Policy and member of Ethics Board in Malaysia, Minden, Malaysia
  • 12 Editor-in-Chief, Value & Outcomes Spotlight and Senior Vice President, Real World Evidence Advisory, INC Research / inVentiv Health, Boston, MA, USA
Value Health, 2017 12;20(10):1227-1242.
PMID: 29241881 DOI: 10.1016/j.jval.2017.10.018

Abstract

As the leading health economics and outcomes research (HEOR) professional society, ISPOR has a responsibility to establish a uniform, harmonized international code for ethical conduct. ISPOR has updated its 2008 Code of Ethics to reflect the current research environment. This code addresses what is acceptable and unacceptable in research, from inception to the dissemination of its results. There are nine chapters: 1 - Introduction; 2 - Ethical Principles respect, beneficence and justice with reference to a non-exhaustive compilation of international, regional, and country-specific guidelines and standards; 3 - Scope HEOR definitions and how HEOR and the Code relate to other research fields; 4 - Research Design Considerations primary and secondary data related issues, e.g., participant recruitment, population and research setting, sample size/site selection, incentive/honorarium, administration databases, registration of retrospective observational studies and modeling studies; 5 - Data Considerations privacy and data protection, combining, verification and transparency of research data, scientific misconduct, etc.; 6 - Sponsorship and Relationships with Others (roles of researchers, sponsors, key opinion leaders and advisory board members, research participants and institutional review boards (IRBs) / independent ethics committees (IECs) approval and responsibilities); 7 - Patient Centricity and Patient Engagement new addition, with explanation and guidance; 8 - Publication and Dissemination; and 9 - Conclusion and Limitations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.